HPLC analysis of suspected COVID-19 therapeutic agent | Oseltamivir

The search for effective therapeutics for COVID-19 patients

In the search for effective therapeutics for COVID-19 patients, active ingredients that have shown treatment success against similar coronaviruses or influenza viruses are also included in studies. The neuraminidase inhibitor Oseltamivir, also known as Tamiflu®(1), has been tested for efficacy at various stages of COVID-19 disease. Although the efficacy of Oseltamivir has not been proven in the stage of acute pneumonia with respiratory distress, there may be indications that early antiviral therapy with the agent (within 24 hours of onset) may reduce fever and may have a generally favorable effect on disease progression(2). Clinical trials investigating the effectiveness of the drug in combination with other agents are ongoing (3)(4).

Access to HPLC application: Separation of Oseltamivir from its three impurities on a MACHEREY-NAGEL fully porous endcapped C8 column.

Structure - Oseltamivir (Tamiflu)


Further examples of drug analysis related to COVID-19


(1) F. Hoffmann-La Roche Ltd.
(2) Ciba, Satoru (2020), DOI://doi.org/10.21203/rs.3.rs-33046/v1
(3) R.Wu, L. Wang et al., Current Pharmacology Reports (2020); 6:56-70
(4) medinfo.roche.com, Covid, 29.04.2020

Related products